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358Objective: Our objective was to compare the oncologic outcomes of lobectomy and segmentectomy for clinical
stage IA lung adenocarcinoma.
Methods: We examined 481 of 618 consecutive patients with clinical stage IA lung adenocarcinoma who
underwent lobectomy or segmentectomy after preoperative high-resolution computed tomography and
F-18-fluorodeoxyglucose positron emission tomography/computed tomography. Patients (n ¼ 137) who under-
went wedge resection were excluded. Lobectomy (n ¼ 383) and segmentectomy (n ¼ 98) as well as surgical
results were analyzed for all patients and their propensity score–matched pairs.
Results: Recurrence-free survival (RFS) and overall survival (OS) were not significantly different between pa-
tients undergoing lobectomy (3-year RFS, 87.3%; 3-year OS, 94.1%) and segmentectomy (3-year RFS, 91.4%;
hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.27-1.20; P ¼ .14; 3-year OS, 96.9%; HR, 0.49; 95%
CI, 0.17-1.38; P¼ .18). Significant differences in clinical factors such as solid tumor size (P<.001), maximum
standardized uptake value (SUVmax) (P<.001), and tumor location (side, P ¼ .005; lobe, P ¼ .001) were
observed between both treatment groups. In 81 propensity score–matched pairs including variables such as
age, gender, solid tumor size, SUVmax, side, and lobe, RFS and OS were similar between patients undergoing
lobectomy (3-year RFS, 92.9%, 3-year OS, 93.2%) and segmentectomy (3-year RFS, 90.9%; 3-year OS,
95.7%).
Conclusions: Segmentectomy is suitable for clinical stage IA lung adenocarcinoma, with survivals equivalent to
those of standard lobectomy. (J Thorac Cardiovasc Surg 2013;146:358-64)Segmentectomy for treating small lung cancer has been
a topic of debate for a long time. In 1995, the Lung Cancer
Study Group conducted a prospective randomized con-
trolled trial comparing limited resection (including segmen-
tectomy and wedge resection) with lobectomy for clinical
T1 N0 M0 non–small cell lung cancer (NSCLC). The study
concluded that limited resection resulted in higher local re-
currence and lower survival.1 A recent study from the Sur-
veillance Epidemiology and End Results database showed
that lobectomy conferred a significant advantage compared
with segmentectomy in stage I NSCLC.2 In contrast, several
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The Journal of Thoracic and Cardiovascular Surgthose after lobectomy were similar.3-7 However, few reports
compare between segmentectomy and lobectomy with
matched patient variables affecting survival.
Recently, we8,9 reported that solid tumor size, defined as
the maximum dimension of the solid component excluding
the ground-glass opacity (GGO) component on high-
resolution computed tomography (HRCT), and maximum
standardized uptake value (SUVmax) on [18F]-fluoro-2-
deoxy-D-glucose positron emission tomography/computed
tomography (FDG-PET/CT), are useful for predicting the
pathologic invasiveness or prognosis in clinical stage IA
lung adenocarcinoma. These preoperative radiologic find-
ings are important when choosing treatment strategies for
NSCLC, particularly for lung adenocarcinoma.8,9
The purpose of this retrospective study was to compare
the oncologic outcomes between lobectomy and segmen-
tectomy in patients with clinical stage IA lung adenocarci-
noma, adjusted for preoperative factors including HRCT
and FDG-PET/CT findings, to minimize the effect of pa-
tient selection bias. Segmentectomy and wedge resection
are considerably different procedures for lung cancer; the
former can be used to approach hilar lymph nodes and to
get sufficient margin, whereas the latter cannot. Therefore,
we excluded wedge resection from this study.ery c August 2013
Abbreviations and Acronyms
CI ¼ confidence interval
FDG-PET/CT ¼ [18F]-fluoro-2-deoxy-D-glucose
positron emission tomography/
computed tomography
GGO ¼ ground-glass opacity
HRCT ¼ high-resolution computed
tomography
NSCLC ¼ non–small cell lung cancer
OS ¼ overall survival
RFS ¼ recurrence-free survival
SUVmax ¼ maximum standardized uptake
value
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SPATIENTS AND METHODS
Patients
We enrolled 618 patients with clinical T1 N0 M0 stage IA lung adeno-
carcinoma from 4 institutions (Hiroshima University, Kanagawa Cancer
Center, Cancer Institute Hospital, and Hyogo Cancer Center, Japan) be-
tween August 1, 2005 and June 30, 2010, to evaluate the significance of
FDG-PET/CT. Patients with incompletely resected tumors (R1 or R2)
and those with multiple tumors or previous lung operations were not in-
cluded in the database. The database has been maintained prospectively.
The patient data obtained from this multicenter database were retrospec-
tively analyzed in the present study. HRCT and FDG-PET/CT followed
by curative R0 resection were performed for all patients staged according
to the TNM Classification of Malignant Tumors, seventh edition.10 Media-
stinoscopy or endobronchial ultrasonography was not routinely performed
because all patients received preoperative HRCT and FDG-PET/CT;
HRCT revealed no swelling of mediastinal or hilar lymph nodes and
FDG-PET showed no accumulation in these lymph nodes. Sublobar resec-
tion was allowed in cases of complete removal of the disease, using the op-
tional procedure instead of lobectomy for a peripheral T1 N0 M0 tumor.
The other patients underwent standard lobectomy. All patients who under-
went segmentectomy were suitable for lobectomy and all patients who un-
derwent lobectomy were technically suitable for segmentectomy. Patients
who had lymph node metastasis pathologically received platinum-based
chemotherapy after operation.
The inclusion criteria were preoperative staging determined by HRCT
and FDG-PET/CT, curative surgery without neoadjuvant chemotherapy
or radiotherapy, and a definitive histopathologic diagnosis of lung adeno-
carcinoma. The study was approved by the institutional review boards of
the participating institutions; the requirement for informed consent from
individual patients was waived because the study was a retrospective re-
view of the patient database. Of the 618 patients, 137 who underwent
wedge resection were excluded; the remaining 481 were included in this
analysis.
HRCT
Sixteen-row multidetector CTwas used to obtain chest images indepen-
dent of subsequent FDG-PET/CT examinations. For high-resolution im-
ages of the tumors, the following parameters were used: 120 kVp, 200
mA, 1- to 2-mm section thickness, 512 3 512-pixel resolution, 0.5- to
1.0-second scanning time, a high-spatial reconstruction algorithm with
a 20-cm field of view, and mediastinal (level, 40 HU; width, 400 HU)
and lung (level, 600 HU; width, 1600 HU) window settings. GGO was
defined as a misty increase in lung attenuation without obscuring theThe Journal of Thoracic and Caunderlying vascular markings. We defined solid tumor size as the maxi-
mum dimension of the solid componentmeasured on lung window settings,
excluding GGO.8 CT scans were reviewed and tumor sizes were deter-
mined by radiologists from each institution.
FDG-PET/CT
Patients were instructed to fast for at least 4 hours before intravenous
injection of 74 to 370 MBq FDG and were then advised to rest for at least
1 hour before FDG-PET/CT scanning. Blood glucose levels were calcu-
lated before the tracer injection to confirm a level of more than 150
mg/dL.11 Patients with blood glucose levels of 150mg/dL or morewere ex-
cluded from the PET/CT imaging. For imaging, Discovery ST (GE Health-
care, Little Chalfont, United Kingdom), Aquiduo (Toshiba Medical
Systems Corporation, Tochigi, Japan), or Biograph Sensation 16 (Siemens
Healthcare, Erlangen, Germany) integrated 3-dimensional PET/CT scan-
ner was used. Low-dose nonenhanced CT images of 2- to 4-mm section
thickness for attenuation correction and localization of lesions identified
by PETwere obtained from the head to the pelvic floor of each patient ac-
cording to a standard protocol.
Immediately after CT, PETwas performed with the identical axial field
of view for 2- to 4-min/table position, depending on the condition of the
patient and the scanner performance. An iterative algorithm with
CT-derived attenuation correction was used to reconstruct all PET images
with a 50-cm field of view. An anthropomorphic body phantom (NEMA
NU2-2001, Data Spectrum Corp, Hillsborough, NC) was used to minimize
the variations in SUVs among the institutions.12 A calibration factor was
analyzed by dividing the actual SUV by the gauged mean SUV in the phan-
tom background to decrease interinstitutional SUV inconsistencies; the
final SUV used in this study is referred to as the revised SUVmax.13,14
When the SUVmax ratio was expressed as the SUVmax of each institute
relative to the SUVmax of the control institute, the adjustment of
interinstitutional variations in SUV narrowed the range from 0.89-1.24 to
0.97-1.18. The original SUVmax values were determined by radiologists
from each institution.Follow-up Evaluation
All patients who underwent lung resection were followed up from the
day of surgery. Postoperative follow-up procedures, including a physical
examination and chest radiograph every 3 months and chest and abdominal
CTexaminations every 6 months, were performed for the first 2 years. Sub-
sequently, a physical examination and chest radiograph were performed
every 6 months, and a chest CT examination was performed every year.
Statistical Analysis
Data are presented as numbers (percent) or the median unless otherwise
stated. The c2 test for categorical variables was used to compare frequen-
cies, and Fisher’s exact test was applied to small samples in all cohorts.
McNemar tests were used to analyze the propensity-matched pair patients.
Both t tests and Mann-Whitney U tests were used to compare continuous
variables in all cohorts. Wilcoxon tests were used to analyze propensity-
matched pair patients. Recurrence-free survival (RFS) was defined as the
time from the day of surgery until the first event (relapse or death from
any cause) or last follow-up. Overall survival (OS) was defined as the
time from the day of surgery until death from any cause or the last
follow-up. The Kaplan-Meier method was used to analyze the duration
of RFS and OS; the Cox proportional hazard model was used to assess dif-
ferences in RFS and OS. We applied propensity score matching to balance
the assignment of the included patients and to correct for the operative pro-
cedure (lobectomy or segmentectomy), which confounded survival calcu-
lations. The variables were age, gender, solid tumor size, SUVmax, side,
and lobe. Because no segmentectomy was performed for a tumor located
at a middle lobe, we excluded patients who underwent middle lobectomy
from the scoring for a fair comparison. Each variable was multiplied byrdiovascular Surgery c Volume 146, Number 2 359
TABLE 1. Patient characteristics
Lobectomy
(n ¼ 383)
Segmentectomy
(n ¼ 98) P value
Age 66 (33-84) 67 (34-89) .08
Gender .75
Male 169 (44.1%) 45 (45.9%)
Whole tumor size (cm) 2.2 (0.8-3.0) 1.7 (0.6-3.0) <.001
Solid tumor size (cm) 1.5 (0-3.0) 0.5 (0-3.0) <.001
SUVmax 2.1 (0-17) 1.2 (0-10) <.001
Side .005
Right 261 (68.4%) 52 (53.1%)
Lobe .001
Upper 200 (52.2%) 50 (51.0%)
Middle 45 (11.7%) 0 (0%)
Lower 138 (36.0%) 48 (49.0%)
Lymphatic invasion 77 (20.1%) 6 (6.1%) .001
Vascular invasion 89 (23.2%) 6 (6.1%) <.001
Pleural invasion 51 (13.3%) 4 (4.1%) .008
Lymph node metastasis 44 (11.5%) 1 (1.0%) <.001
SUVmax, Maximum standardized uptake value.
TABLE 2. Details of segmentectomy (n ¼ 98)
Site No. Site No.
Right Left
S1 4 S1 þ 2 7
S2 12 S3 3
S3 3 S1 þ 2 þ 3 10
S6 23 S1 þ 2 þ 3c 1
S8 5 S4 2
S7 þ 8 1 S5 1
S8 þ 9 3 S4 þ 5 7
S7 þ 8 þ 9 þ 10 1 S6 10
S8 1
S9 3
S6 þ 8 þ 9 þ 10 1
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Sa coefficient that was calculated using logistic regression analysis, and the
sum of these values was taken as the propensity score for individual pa-
tients. C statistic of variables was 0.819 (95% confidence interval [CI],
0.776-0.863; P<.0001). After the calculation of their propensity scores,
the subjects were divided into 3 groups according to tertile to compare
characteristics between lobectomy and segmentectomy in each tertile.
For matching, lobectomy and segmentectomy pairs with an equivalent pro-
pensity score were selected by a 1-to-1 match. Statistical Package for the
Social Sciences (SPSS) software (version 10.5; SPSS Inc, Chicago, Ill)
was used to statistically analyze the data.RESULTS
Table 1 summarizes the characteristics of the 481
patients analyzed in this study. Of these, 383 patients un-
derwent lobectomy and 98 patients underwent segmentec-
tomy. There was no 30-day postoperative mortality in this
population. The median follow-up period after surgery was
43.2 months, during which the tumor recurred in 50 pa-
tients. There were 20 local-only recurrences, including me-
diastinal lymph node metastasis, and 30 distant  local
recurrences. Age and gender were not significantly differ-
ent between patients who underwent lobectomy and those
who underwent segmentectomy. Lobectomy was per-
formed significantly more often for patients with large
whole and solid tumor size, high SUVmax, pathologically
invasive tumors (presence of lymphatic, vascular, or pleu-
ral invasion), and lymph node involvement. Tumor loca-
tion was significantly different between patients who
underwent lobectomy and those who underwent segmen-
tectomy. Detailed procedures in segmentectomy were
shown in Table 2.
Local recurrence occurred in 17 patients who underwent
lobectomy (2 involving the bronchial stump, 1 involving the
hilar lymph nodes, 11 involving the mediastinal lymph
nodes, and 3 involving the pleura) and 3 patients who360 The Journal of Thoracic and Cardiovascular Surgunderwent segmentectomy (1 involving the residual lobe,
1 involving the surgical stump, and 1 involving the pleura).
Table 3 shows the multivariate analyses of distant and
local RFS. Gender, solid tumor size, and SUVmax were sig-
nificant independent prognostic factor for distant RFS,
whereas whole tumor size was not. Regarding local RFS,
solid tumor size and SUVmax were independent prognostic
factors, but whole tumor size was not. RFS was not
significantly different between patients who underwent
lobectomy (3-year RFS, 87.3%) compared with segmentec-
tomy (3-year RFS, 91.4%; hazard ratio [HR], 0.57; 95%
CI, 0.27-1.20; P ¼ .14, Figure 1, A). OS was not signifi-
cantly different between patients who underwent lobectomy
(3-year OS, 94.1%) compared with segmentectomy (3-year
OS, 96.9%; HR, 0.49; 95% CI, 0.17-1.38; P ¼ .18;
Figure 1, B).
After the calculation of the propensity score, the subjects
were divided into 3 groups according to tertile (Table 4).
The numbers of patients in tertiles 1, 2, and 3 according
to the operative procedures (lobectomy; segmentectomy)
were 79 and 66, 118 and 27, and 141 and 5, respectively.
Solid tumor size was smaller and SUVmax was lower in
the lowest tertile group, indicating that segmentectomy
trended to be performed in patients with a tumor of smaller
solid tumor size and lower SUVmax. There were some dif-
ferences in background characteristics, especially in the
lowest tertile group. Therefore, we performed propensity
score matching to compare the survival between lobectomy
and segmentectomy groups.
When propensity score matching was used and variables
such as age, gender, solid tumor size, SUVmax, side, and
lobe were included, lobectomy and segmentectomy pairs
were well matched (81 patients each) without significant
differences in clinical and pathologic factors (Table 5).
Among propensity score–matched patients, no difference
in RFS was identified between patients who underwent
lobectomy (3-year RFS, 92.9%) compared with segmentec-
tomy (3-year RFS, 90.9%; Figure 1, C). In addition, similar
OSs were observed between patients who underwentery c August 2013
TABLE 3. Multivariate analyses for distant or local RFS
Variables HR (95% CI) P value
Multivariate analysis for distant RFS
Model 1
Age 1.00 (0.96-1.04) .86
Gender
Male vs female 2.62 (1.15-5.95) .022
Whole tumor size (cm) 1.17 (0.60-2.27) .65
SUVmax 1.26 (1.14-1.39) <.001
Procedure
Lobectomy vs segmentectomy 1.44 (0.41-5.00) .57
Model 2
Age 1.00 (0.96-1.03) .80
Gender
Male vs female 2.57 (1.14-5.78) .023
Solid tumor size (cm) 1.86 (1.09-3.16) .023
SUVmax 1.19 (1.06-1.34) .003
Procedure
Lobectomy vs segmentectomy 0.90 (0.24-3.36) .88
Multivariate analysis for local RFS
Model 1
Age 1.04 (0.99-1.10) .15
Gender
Male vs female 0.59 (0.24-1.46) .26
Whole tumor size (cm) 1.44 (0.66-3.12) .94
SUVmax 1.17 (1.03-1.33) .015
Procedure
Lobectomy vs segmentectomy 1.06 (0.29-3.86) .36
Model 2
Age 1.04 (0.98-1.09) .19
Gender
Male vs female 0.58 (0.24-1.43) .24
Solid tumor size (cm) 2.89 (1.52-5.50) .001
SUVmax 1.09 (0.94-1.27) .26
Procedure
Lobectomy vs segmentectomy 0.54 (0.14-2.13) .38
RFS, Recurrence-free survival; HR, hazard ratio; CI, confidence interval; SUVmax,
maximum standardized uptake value.
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tomy (3-year OS, 95.7%; Figure 1, D).DISCUSSION
The current study compared oncologic outcomes between
patients who underwent lobectomy and segmentectomy for
clinical stage IA lung adenocarcinoma. In all cohorts,
when preoperative clinical factors were not adjusted, RFS
and OS of the segmentectomy group were not significantly
different from those of the lobectomy group. The survival
curves of the segmentectomy group appeared to be better
than those of the lobectomy group. However, each patient
group was different in terms of solid tumor size and
SUVmax, which could affect the patient’s survival.8,9,13-16
In addition, the number of patients who had lymph node
metastasis was inevitably larger in the lobectomy groupThe Journal of Thoracic and Cathan in the segmentectomy group, which also could affect
the survival. To minimize patient selection bias, we used
propensity score matching analyses. In the model that
matched for potentially confounding variables such as
age, gender, solid tumor size, SUVmax, tumor location, in
lobectomy and segmentectomy pairs, there were no
significant differences in clinical features or pathologic
factors such as lymphatic, vascular, pleural invasion, or
lymph node metastasis. Even in our matched model, RFS
and OS in the segmentectomy group was similar to the
lobectomy group, indicating that segmentectomy could be
an optimal surgical procedure for clinical stage IA lung
adenocarcinoma selected on the basis of HRCT and
FDG-PET/CT.
The strength of this study was that variables such as
findings from HRCT (solid tumor size) and FDG-PET
(SUVmax) were included in the propensity score–matched
analysis. We reported that solid tumor size on HRCT and
SUVmax on FDG-PET/CT had higher predictive values
with respect to pathologic invasiveness such as lymphatic,
vascular, pleural invasion, and prognosis compared with
whole tumor size.8,9 In addition, once matching for solid
tumor size and SUVmax, pure solid tumor and solid
tumor with GGO showed equivalent survivals.17 Indeed,
whole tumor size was not an independent factor for distant
or local RFS in this study, whereas solid tumor size and
SUVmax were. Solid tumor size does represent tumor ma-
lignancy compared with whole tumor size. Therefore, we
did not include whole tumor size in matching variables. In-
asmuch as SUVmax on FDG-PET/CT was a prognostic in-
dicator for lung adenocarcinoma, not for squamous cell
carcinoma in our previous study,16 the database included
only adenocarcinoma, which is a major histologic type for
NSCLC. Although several studies have indicated equivalent
survivals for segmentectomy and lobectomy in patients
with clinical stage IA lung cancer, to our knowledge, this
is the first study adjusting for preoperative HRCT and
FDG-PET/CT findings, both of which should be considered
when selecting patients for limited resections such as seg-
mentectomy. Furthermore, we used an anthropomorphic
body phantom to minimize the interinstitutional variability
in SUV, which may be influenced by factors such as prepa-
ration procedures, scan acquisition, image reconstruction,
and data analysis.
Most previous studies that showed favorable outcomes
with segmentectomy indicated this procedure for T1 N0
M0 NSCLC of 2 cm or less.4-6 We included patients with
a whole tumor size of 2 to 3 cm (ie, clinical T1b tumor)
in this study. We9 have reported that patients with T1b
lung adenocarcinomas selected on the basis of HRCT and
FDG-PET/CT findings could be candidates for sublobar re-
section with a sufficient surgical margin. Inasmuch as clin-
ical T1b N0 M0 lung adenocarcinomas occasionally show
large GGO components and/or low SUVmax (signs ofrdiovascular Surgery c Volume 146, Number 2 361
FIGURE 1. Recurrence-free survival (RFS) curves and overall survival (OS) curves for patients who underwent lobectomy and segmentectomy. A, In all
cohorts, 3-year RFSs of 87.3% (mean RFS, 66.8 months; 95% confidence interval [CI], 64.6-69.4 months) and 91.4% (mean RFS, 70.3 months; 95% CI,
66.9-73.8 months) were identified for patients who underwent lobectomy and segmentectomy, respectively (hazard ratio [HR], 0.57; 95% CI, 0.27-1.20;
P¼ .14). B, In all cohorts, 3-year OSs of 94.1% (mean OS, 70.4 months; 95%CI, 68.7-72.1months) and 96.9% (mean OS, 72.9months; 95%CI, 70.3-75.4
months) were identified for patients who underwent lobectomy and segmentectomy, respectively (HR, 0.49; 95% CI, 0.17-1.38; P¼ .18). C, In propensity
score–matched patients, 3-year RFSs of 92.9% (mean RFS, 68.6 months; 95% CI, 64.9-72.2 months) and 90.9% (mean RFS, 70.2 months; 95% CI,
66.4-73.9 months) were identified for patients who underwent lobectomy and segmentectomy, respectively. D, In propensity score–matched patients,
3-year OSs of 93.2% (mean OS, 69.3 months; 95% CI, 65.8-72.7 months) and 95.7% (mean OS, 73.2 months; 95% CI, 70.6-75.8 months) were identified
for patients who underwent lobectomy and segmentectomy, respectively.
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Slow malignant behavior), such tumors could be treated with
lesser resection.9
This study has several limitations. Because this study was
retrospective, patients who underwent segmentectomy were
possibly highly selective. In addition, we could not match
intended procedures in the study because the database in-
cluded only performed surgical procedures, not intended
procedures, and patients with R1 or R2 resection were never
included in the database. Most patients who underwent362 The Journal of Thoracic and Cardiovascular Surgsegmentectomy in this study tended to have relatively
low-malignancy tumors, with small solid tumor size and/
or low SUVmax, and thus low pathologic invasiveness.
The present study revealed that large solid tumor size on
HRCT and high SUVmax on FDG-PET/CT were signifi-
cantly associated with both local and distant recurrences.
The outcome of segmentectomy for relatively high-
malignancy clinical stage IA lung adenocarcinomas with
large solid tumor size and high SUVmax is unclear.ery c August 2013
TABLE 4. Patient characteristics divided into 3 groups according to tertile based on the propensity score
Tertile 1 Tertile 2 Tertile 3
L (n ¼ 79) S (n ¼ 66) P value L (n ¼ 118) S (n ¼ 27) P value L (n ¼ 141) S (n ¼ 5) P value
Age 68 (48-82) 68.5 (42-89) .53 65 (40-83) 65 (34-86) .92 65 (33-84) 64 (53-83) .5
Gender .87 .28 1.0
Male 36 (45.6%) 29 (43.9%) 46 (39.0%) 14 (51.9%) 65 (46.1%) 2 (40.0%)
Whole tumor size (cm) 2.0 (0.8-3.0) 1.7 (0.9-3.0) .01 1.8 (1.0-3.0) 1.6 (0.6-2.9) .048 2.5 (1.2-3.0) 2.4 (1.5-3.0) .51
Solid tumor size (cm) 0.5 (0-2.0) 0.3 (0-1.0) .056 1.4 (0-2.0) 1.2 (0-2.0) .03 2.3 (1.0-3.0) 2.2 (1.0-3.0) .71
SUVmax 1.2 (0-4.9) 1.0 (0-4.1) .002 1.9 (0.6-8.3) 1.9 (0.4-9.8) .77 3.9 (0.7-16.9) 2.1 (1.5-4.3) .13
Side .41 1.0 1.0
Right 44 (55.7%) 32 (48.5%) 69 (58.5%) 16 (59.3%) 103 (73.0%) 4 (80.0%)
Lobe .51 .53 1.0
Upper 41 (51.9%) 30 (45.5%) 66 (55.9%) 17 (63.0%) 93 (66.0%) 3 (60.0%)
Lower 38 (48.1%) 36 (54.5%) 52 (44.1%) 10 (37.0%) 48 (34.0%) 2 (40.0%)
L, Lobectomy; S, segmentectomy; SUVmax, maximum standardized uptake value.
Tsutani et al General Thoracic Surgery
G
T
SAlthough surgical procedure did not correlate with local or
distant recurrence in this study, segmentectomy for such tu-
mors (ie, with large solid tumor size or high SUVmax)
should be carefully considered. A clinical trial is being con-
ducted by the Japanese Clinical Oncology Group/West
Japan Oncology Group (JCOG0802/WJOG4607L), which
aims to compare the surgical results between lobectomy
and segmentectomy for T1 N0 M0 NSCLC measuring 2
cm or less.18 This prospective study includes patients with
radiologically invasive tumors, such as solid dominant tu-
mors, that have large solid tumor size on HRCT. The results
of this trial may provide an important insight into this issue.
Segmentectomy is beneficial because it preserves lung
function. Although the database used in this study did not
incorporate lung function data, several reports haveTABLE 5. Propensity score–matched comparison of clinical and
pathologic factors between patients who underwent lobectomy and
segmentectomy
Lobectomy
(n ¼ 81)
Segmentectomy
(n ¼ 81) P value
Clinical factors
Age 66 (48-82) 65 (34-86) .68
Gender .74
Male 37 (45.6%) 34 (42.0%)
Whole tumor size (cm) 2.0 (1.0-3.0) 1.7 (0.6-3.0) .11
Solid tumor size (cm) 0.7 (0-2.0) 0.8 (0-3.0) .17
SUVmax 1.4 (0-7.0) 1.2 (0-9.8) .23
Side .63
Right 33 (40.7%) 37 (45.6%)
Lobe .23
Upper 51 (63.0%) 43 (53.1%)
Lower 30 (37.0%) 38 (46.9%)
Pathologic factors
Lymphatic invasion 10 (12.3%) 6 (7.4%) .42
Vascular invasion 6 (7.4%) 6 (7.4%) 1.0
Pleural invasion 7 (8.6%) 4 (4.9%) .45
Lymph node metastasis 3 (3.7%) 1 (1.2%) .63
SUVmax, Maximum standardized uptake value.
The Journal of Thoracic and Cademonstrated that segmentectomy has functional advan-
tages over lobectomy.5,19,20 If similar oncologic outcomes
are expected, segmentectomy should be considered for
patients with clinical stage IA lung adenocarcinoma.
In conclusion, the oncologic outcomes of segmentec-
tomy are similar to those of standard lobectomy for patients
with clinical stage IA lung adecnocarcinoma, as determined
by the matched model adjusting for preoperative clinical
factors such as HRCTand FDG-PET/CT findings. Segmen-
tectomy could be favorable for selective patients with stage
IA lung adenocarcinoma.References
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